Firm Profile

Lawrence S. PerryLawrence S. PerryPartner, New York

Professional Experience

Lawrence S. Perry has extensive experience practicing before the U.S. Patent and Trademark Office, including appeals, interferences, reexaminations, reissues and all phases of patent prosecution in biotechnical, chemical, pharmaceutical, plant genetics, magneto-optical, metallurgical and mechanical technologies. Mr. Perry has extensive opinion work concerning noninfringement, invalidity and freedom to practice in these and other fields.

Mr. Perry has also lectured at various professional law associations:

  • Lecturer, Advanced Patent Prosecution, Practicing Law Institute, July 26-27, 2010
  • Lecturer, Patenting in the Biological Arts, Joint Japanese Symposium, October 7, 2009
  • Lecturer, Schendel v. Curtis, New York Intellectual Property Law Association, Joint Patent Seminar, May 30, 1997
  • Lecturer, Utility Requirements in Biotechnology Patent Applications, Philadelphia Intellectual Property Law Association, Joint Patent Seminar, April 12, 1995
  • Lecturer, Patenting and Licensing of Human Monoclonal Antibodies, International Business Communications Annual Conference, February 7, 1994
  • Lecturer, Understanding Monoclonal Antibodies, Hybridomas and Other Exotic Technologies, AIPLA Mid-Winter Conference, January 25, 1994
  • Lecturer, Organizing Your Appeal Brief, Symposium on Practice Before the U.S.P.T.O. Board of Patent Appeals and Interferences, June 10, 1991

Awards and Recognition

Mr. Perry is listed in Legal 500 2008 for patent re-examination. He was also recognized in the 2011 edition of Who’s Who of Patent Lawyers.

For information on the selection process, see:

Legal 500
Who's Who Legal


J.D., with honors, IIT/Chicago-Kent College of Law, 1984
B.A., Biochemistry and Molecular Biology, Northwestern University, 1981

Bar Admissions

State of New York, 1989; State of Illinois, 1984; U.S. District Courts for the Northern District of Illinois; U.S. District Courts for the Southern and Eastern Districts of New York; U.S. Patent and Trademark Office

Professional Activities

American and New York Bar Associations (ABA IPL Committee and Patent, Trademark and Copyright Section Committee on Reexamination); American and New York Intellectual Property Lawyers Associations (AIPLA Biotechnology and Interference Committees); Intellectual Property Owners Association (IPO Patent Law Committee); Biotechnology Industry Organization; New York Biotechnology Association

Additional Publications

“Hot Topic: The Mayo v. Prometheus decision,” Pharmaceutical Analyst, 2012

“Property Rights in Living Matter: Is New Law Required?,” 68 Den.U.L.Rev.2.

Representative Matters

Some of the Representative Matters Mr. Perry has worked on include:

Notable Prosecution

U.S. Patent No. 6,197,819 for gamma amino butyric acid analogs and optical isomers (on behalf of Kohn & Associates for Northwestern University), licensed to Pfizer Inc. and Eisai Pharmaceuticals covering Lyrica, with $5.2B global 2014 sales. Validity and infringement confirmed (Pfizer Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2012)) and affirmed on appeal (Pfizer Inc. v. Teva Pharmaceuticals USA, Inc. (Fed. Cir. 2014)).


Interference No. 102,090 involving circuit for driving multi element display devices.

Interference No. 102,091 involving method of maintaining display state in liquid crystal devices.

Interference No. 102,092 involving ferroelectric liquid crystal optical displays.

Interference No. 102,323 involving method of addressing liquid crystal displays.

Interference No. 102,393 involving DNA encoding GM-CSF.

Interference No. 103,046 involving method of producing misoprostol.

Interference No. 103,424 involving bone morphogenic proteins.

Interference No. 104,539 involving photocurable cyanoacrylate compositions.


Application No. 14/329,255 for process for producing amino acid.

Application No. 14/517,148 for antibodies to human IL-1β.

Application No. R8/520,642 for porphyrins.


Application No. 90/001,306 for LED with epitaxial wafer.

Application No. 90/002,675 for optimized double-press sinter powder metallurgy method.

Application No. 90/012,707 for methods of improving display uniformity of organic LED by calibrating individual pixel.

Appeals (USPTO)

US Application No. 07/474,648 for producing L-threonine and L-glutamic acid using Corynebacterium or Brevibacterium containing E. coli THR operon or phosphoenolpyruvic acid decarboxylase genes.

US Application No. 07/846,776 for cyclic nucleotide phosphodiesterase inhibitors.

US Application No. 08/579,731 for optically active 2R,4S benzothiepin isomer.

US Application No. 10/271,710 for preserving process sensitive ingredients in energy food product.

US Application No. 10/940,026 for producing complex carbohydrate using Corynebacterium culture and nucleotide triphosphate.

US Application No. 11/815,225 for determining cholesterol in remnant-like particles.

US Application No. 12/700,367 for laser handpiece with fiber optic insert and control unit.

US Application No. 13/032,127 for producing fermentation product from sugar hydrolysate.


The Amgen v. Sandoz BPCIA Decision Stands: the Federal Circuit Denies an En Banc Rehearing
Fitzpatrick Case Update
October 22, 2015
IP Monetisation Due Diligence: The Duration of Exclusivity II
Financier Worldwide
October 2011
Untangling the Nanothreads Between the Enablement and Written Description Requirements
Nanotechnology Law & Business
March 2007


Fitzpatrick Honored by The Legal Aid Society
The Legal Aid Society
November, 2011
Fitzpatrick listed in the International Who's Who of Patent Lawyers 2011
Who's Who Legal
May 2011